MCID: MLR004
MIFTS: 83

Malaria

Categories: Genetic diseases, Rare diseases, Infectious diseases

Aliases & Classifications for Malaria

MalaCards integrated aliases for Malaria:

Name: Malaria 57 38 12 76 53 59 55 43 3 44 15 73
Malaria, Cerebral 57 44 73
Malaria, Cerebral, Susceptibility to 57 6
Malaria, Severe, Susceptibility to 57 6
Malaria, Severe, Resistance to 57 6
Susceptibility to Malaria 29 6
Malaria, Resistance to 57 6
Cerebral Malaria 12 15
Induced Malaria 12 73
Resistance to Malaria Due to G6pd Deficiency 57
Malaria, Vivax, Protection Against 57
Malaria, Cerebral, Reduced Risk of 57
Malaria Due to G6pd Deficiency 57
Malaria, Protection Against 57
Malaria, Susceptibility to 57
Malarial Encephalitis 12
Malaria Cerebral 55
Malaria, Severe 57

Characteristics:

Orphanet epidemiological data:

59
malaria
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


Summaries for Malaria

OMIM : 57 Malaria, a major cause of child mortality worldwide, is caused by mosquito-borne hematoprotozoan parasites of the genus Plasmodium. Of the 4 species that infect humans, P. falciparum causes the most severe forms of malaria and is the major cause of death and disease. Although less fatal, P. malariae, P. ovale, and, in particular, P. vivax infections are major causes of morbidity. The parasite cycle involves a first stage in liver cells and a subsequent stage at erythrocytes, when malaria symptoms occur. A wide spectrum of phenotypes are observed, from asymptomatic infection to mild disease, including fever and mild anemia, to severe disease, including cerebral malaria, profound anemia, and respiratory distress. Genetic factors influence the response to infection, as well as disease progression and severity. Malaria is the strongest known selective pressure in the recent history of the human genome, and it is the evolutionary driving force behind sickle-cell disease (603903), thalassemia (see 141800), glucose-6-phosphatase deficiency (300908), and other erythrocyte defects that together constitute the most common mendelian diseases of humans (Kwiatkowski, 2005; Campino et al., 2006). (611162)

MalaCards based summary : Malaria, also known as malaria, cerebral, is related to plasmodium falciparum malaria and plasmodium vivax malaria, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Malaria is HBB (Hemoglobin Subunit Beta), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Artesunate and Dihydroartemisinin have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and brain, and related phenotypes are anemia and acute kidney injury

Disease Ontology : 12 A parasitic protozoa infectious disease characterized as a vector-borne infectious disease caused by the presence of protozoan parasites of the genus Plasmodium in the red blood cells, transmitted from an infected to an uninfected individual by the bite of anopheline mosquitoes, and characterized by periodic attacks of chills and fever that coincide with mass destruction of blood cells and the release of toxic substances by the parasite at the end of each reproductive cycle.

NIH Rare Diseases : 53 Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. Infection with malaria parasites may result in a wide variety of symptoms, ranging from absent or very mild symptoms to severe disease and even death. People who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. In general, malaria is a curable disease if diagnosed and treated promptly and correctly. Treatment depends on many factors including disease severity, the species of malaria parasite causing the infection and the part of the world in which the infection was acquired.

MedlinePlus : 43 Malaria is a serious disease caused by a parasite. You get it when an infected mosquito bites you. Malaria is a major cause of death worldwide, but it is almost wiped out in the United States. The disease is mostly a problem in developing countries with warm climates. If you travel to these countries, you are at risk. There are four different types of malaria caused by four related parasites. The most deadly type occurs in Africa south of the Sahara Desert. Malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. A blood test can diagnose it. It can be life-threatening. However, you can treat malaria with drugs. The type of drug depends on which kind of malaria you have and where you were infected. Malaria can be prevented. When traveling to areas where malaria is found See your doctor for medicines that protect you Wear insect repellent with DEET Cover up Sleep under mosquito netting Centers for Disease Control and Prevention

Wikipedia : 76 Malaria is a mosquito-borne infectious disease affecting humans and other animals caused by parasitic... more...

Related Diseases for Malaria

Diseases related to Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 394)
# Related Disease Score Top Affiliating Genes
1 plasmodium falciparum malaria 36.6 CD36 CR1 FCGR2A G6PD HBB ICAM1
2 plasmodium vivax malaria 36.4 ACKR1 G6PD ICAM1 IFNG IL10 TNF
3 filariasis 32.9 IFNG IL10 TLR9 TNF
4 leishmaniasis 32.8 IFNG IL10 NOS2 TLR9 TNF
5 trypanosomiasis 32.7 ICAM1 IFNG IL10 TLR9 TNF
6 schistosomiasis 32.5 IFNG IL10 TNF
7 meningitis 32.4 FCGR2A IFNG IL10 TLR9 TNF
8 visceral leishmaniasis 32.3 IFNG IL10 NOS2 TLR9 TNF
9 systemic lupus erythematosus 32.2 CR1 FCGR2A FCGR2B ICAM1 IFNG IL10
10 chagas disease 32.2 IFNG IL10 NOS2 TNF
11 toxoplasmosis 32.2 IFNG IL10 TLR9 TNF
12 hemophagocytic lymphohistiocytosis 32.1 CR1 IFNG IL10 TNF
13 hemorrhagic fever 32.0 IFNG IL10 TNF
14 dengue hemorrhagic fever 32.0 FCGR2A IFNG IL10 TNF
15 sickle cell anemia 31.9 ACKR1 HBB TNF
16 pulmonary edema 31.9 ICAM1 IL10 TNF
17 bacterial meningitis 31.9 IL10 TLR9 TNF
18 multiple sclerosis 31.8 ICAM1 IFNG IL10 NOS2 TLR9 TNF
19 dermatitis, atopic 31.8 ICAM1 IFNG IL10 TLR9 TNF
20 myocarditis 31.8 ICAM1 NOS2 TNF
21 autoimmune disease 31.8 FCGR2A FCGR2B IFNG IL10 TLR9 TNF
22 coccidiosis 31.8 IFNG IL10 TLR9 TNF
23 bronchiolitis 31.7 IFNG IL10 TLR9 TNF
24 psoriasis 31.6 ICAM1 IFNG IL10 TLR9 TNF
25 q fever 31.6 IFNG IL10 TNF
26 echinococcosis 31.6 IFNG IL10 TNF
27 parasitic helminthiasis infectious disease 31.5 IL10 TLR9 TNF
28 bronchiolitis obliterans 31.5 IFNG IL10 TNF
29 endomyocardial fibrosis 31.5 IL10 TNF
30 tropical endomyocardial fibrosis 31.5 IL10 TNF
31 acquired immunodeficiency syndrome 31.4 IFNG IL10 TNF
32 pre-eclampsia 31.2 ICAM1 IL10 NOS2 TNF
33 tungiasis 31.1 IL10 TNF
34 plasmodium malariae malaria 12.5
35 plasmodium ovale malaria 12.4
36 mixed malaria 12.3
37 malaria, mild 12.0
38 parasitic protozoa infectious disease 11.8 ACKR1 GYPA ICAM1 IFNG IL10 TLR9
39 blackwater fever 11.8
40 hereditary spherocytosis 11.8 G6PD GYPA GYPB GYPC HBB SLC4A1
41 immune system disease 11.8 HBB IFNG IL10 TLR9 TNF
42 respiratory system disease 11.8 ICAM1 IFNG IL10 TLR9 TNF
43 poliomyelitis 11.7 FCGR2A ICAM1 IFNG IL10 TNF
44 autoinflammation, lipodystrophy, and dermatosis syndrome 11.7 ICAM1 IFNG IL10 NOS2 TNF
45 nervous system disease 11.7 IFNG IL10 NOS2 TLR9 TNF
46 cytomegalovirus infection 11.7 ICAM1 IFNG IL10 TNF
47 lepromatous leprosy 11.7 ICAM1 IFNG IL10 TNF
48 colitis 11.7 IFNG IL10 NOS2 TLR9 TNF
49 lichen disease 11.7 ICAM1 IFNG TLR9 TNF
50 nose disease 11.7 ICAM1 IL10 TLR9 TNF

Graphical network of the top 20 diseases related to Malaria:



Diseases related to Malaria

Symptoms & Phenotypes for Malaria

Clinical features from OMIM:

611162

Human phenotypes related to Malaria:

59 32 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001903
2 acute kidney injury 59 32 hallmark (90%) Very frequent (99-80%) HP:0001919
3 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
4 morphological abnormality of the central nervous system 59 32 hallmark (90%) Very frequent (99-80%) HP:0002011
5 nausea and vomiting 59 32 hallmark (90%) Very frequent (99-80%) HP:0002017
6 headache 59 32 hallmark (90%) Very frequent (99-80%) HP:0002315
7 elevated c-reactive protein level 59 32 hallmark (90%) Very frequent (99-80%) HP:0011227
8 thrombocytopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001873
9 respiratory distress 59 32 frequent (33%) Frequent (79-30%) HP:0002098
10 gait imbalance 59 32 frequent (33%) Frequent (79-30%) HP:0002141
11 hyperbilirubinemia 59 32 frequent (33%) Frequent (79-30%) HP:0002904
12 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
13 reduced consciousness/confusion 59 32 frequent (33%) Frequent (79-30%) HP:0004372
14 cognitive impairment 59 32 frequent (33%) Frequent (79-30%) HP:0100543
15 retinopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0000488
16 abnormality of blood and blood-forming tissues 59 Frequent (79-30%)

UMLS symptoms related to Malaria:


angina pectoris, chest pain, edema, fever, pruritus, remittent fever

MGI Mouse Phenotypes related to Malaria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 FCGR2B TIRAP G6PD ICAM1 IFNG IL10
2 hematopoietic system MP:0005397 9.97 TIRAP G6PD TLR9 ICAM1 TNF IFNG
3 digestive/alimentary MP:0005381 9.86 TLR9 ICAM1 TNF IFNG IL10 CD36
4 homeostasis/metabolism MP:0005376 9.77 TIRAP G6PD TLR9 ICAM1 TNF IFNG
5 immune system MP:0005387 9.44 TIRAP TLR9 ICAM1 TNF IFNG ACKR1

Drugs & Therapeutics for Malaria

Drugs for Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 385)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Artesunate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88495-63-0 6917864 5464098
2
Dihydroartemisinin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71939-50-9 6918483
3
Mefloquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53230-10-7 4046
4
Permethrin Approved, Investigational Phase 4,Phase 3,Not Applicable 52645-53-1 40326
5
Piperaquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4085-31-8 5079497
6
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-34-6 4908
7
Quinine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 130-95-0 8549 3034034
8
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71963-77-4 119380 68911
9
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82186-77-4 6437380
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
11
Amodiaquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 86-42-0 2165
12
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-05-7 2719
13
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-14-0 4993
14
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2447-57-6 17134
15
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable 103-90-2 1983
16
Albendazole Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 54965-21-8 2082
17
Praziquantel Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 55268-74-1 4891
18
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 55185 447043
19
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 723-46-6 5329
20
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 738-70-5 5578
21
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 154598-52-4 64139
22
Nevirapine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 129618-40-2 4463
23
Rifampicin Approved Phase 4,Phase 2,Phase 1 13292-46-1 5458213 5381226
24
Atovaquone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95233-18-4 74989
25
Proguanil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 500-92-5 4923
26
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 7439-89-6 23925
27
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1 118-42-3 3652
28
Doxycycline Approved, Investigational, Vet_approved Phase 4,Not Applicable,Early Phase 1 564-25-0 54671203
29
Morphine Approved, Investigational Phase 4 57-27-2 5288826
30
Copper Approved, Investigational Phase 4,Phase 3,Not Applicable 7440-50-8 27099
31
Hydroxocobalamin Approved Phase 4,Phase 3,Not Applicable 13422-51-0 11953898 44475014
32
Iodine Approved, Investigational Phase 4,Phase 3,Not Applicable 7553-56-2 807
33
Selenium Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 7782-49-2
34
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 23994
35
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
36
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80-08-0 2955
37
Ibuprofen Approved Phase 4,Phase 2,Not Applicable 15687-27-1 3672
38
Lopinavir Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 192725-17-0 92727
39
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 155213-67-5 392622
40
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 70288-86-7 6474909
41
Abacavir Approved, Investigational Phase 4,Phase 3 136470-78-5 65140 441300
42
Lamivudine Approved, Investigational Phase 4,Phase 3,Early Phase 1 134678-17-4 60825
43
Zidovudine Approved Phase 4,Phase 3,Early Phase 1 30516-87-1 35370
44
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
45
Hydroxyurea Approved Phase 4,Phase 3,Not Applicable 127-07-1 3657
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
47
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11103-57-4, 68-26-8 445354
49
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 68-19-9 44176380
50
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 13422-55-4

Interventional clinical trials:

(show top 50) (show all 1183)
# Name Status NCT ID Phase Drugs
1 Malaria Elimination Pilot Study in Military Forces in Cambodia Unknown status NCT02653898 Phase 4 DHA-PIP;Primaquine;Artesunate + Mefloquine;Permethrin (Insecticide treated uniform)
2 Targeted Indoor Residual Spraying Against Malaria Unknown status NCT02556242 Phase 4
3 Intravenous Artesunate and Malaria Unknown status NCT01805232 Phase 4 artesunate;Quinine
4 Impact of Insecticide Resistance on Vector Control Unknown status NCT01713517 Phase 4
5 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
6 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
7 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Unknown status NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
8 Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children Unknown status NCT00540202 Phase 4 artemether-lumefantrine;Oral quinine
9 The Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) for Malaria Prevention Unknown status NCT01697852 Phase 4
10 The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy Unknown status NCT01906788 Phase 4 Artemether Lumefantrine;Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0;Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
11 Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal Unknown status NCT00712374 Phase 4 sulfadoxine-pyrimethamine plus amodiaquine
12 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
13 Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam Unknown status NCT02610686 Phase 4 Chloroquine
14 The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau Unknown status NCT00137566 Phase 4 acetaminophen (paracetamol)
15 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
16 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
17 Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
18 P. Falciparum Resistance to Artemisinin in Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
19 Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection Unknown status NCT02364583 Phase 4 Primaquine
20 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4 Artesunate;Mefloquine
21 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
22 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
23 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
24 A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women Unknown status NCT02575755 Phase 4 Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
25 Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria Unknown status NCT01636895 Phase 4 Efficacy of suphladoxine/pyrimethamine as IPTp;Efficacy of suphladoxine/pyrimethamine as IPTp
26 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
27 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
28 Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine Unknown status NCT00168610 Phase 4 Vitamin A
29 Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts Completed NCT02536222 Phase 4
30 ANC & Malaria Diagnostic in Pregnancy Completed NCT01703884 Phase 4 ASAQ
31 In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure Completed NCT02590627 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
32 The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level Completed NCT01907672 Phase 4
33 Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana Completed NCT01651416 Phase 4 Artemether-lumefantrine combination;Dihydroartemisinin Piperaquine combination;Amodiaquine plus sulphadoxine-pyrimethamine combination
34 Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial Completed NCT00832754 Phase 4
35 Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers Completed NCT02788864 Phase 4 Arterakine (DHA/piperaquine);Placebo
36 Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria Completed NCT01150344 Phase 4 Malarone (atovaquone + proguanil combination);RIAMET (artemether + LUMEFANTRIN combination)
37 Home Management of Malaria and Pneumonia Completed NCT02151578 Phase 4
38 Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Ethiopia Completed NCT01160809 Phase 4
39 Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya Completed NCT01669941 Phase 4 IPTp-SP;IPTp-DP;ISTp-DP
40 A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®) Completed NCT01256658 Phase 4 COA566
41 The Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities Completed NCT00351013 Phase 4
42 The Synergistic Effects of Home-management and Intermittent Preventive Treatment of Malaria in Children Completed NCT00550160 Phase 4 Amodiaquine plus Artesunate co-administration
43 Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra Completed NCT01389557 Phase 4 Dihydroartemisinin-piperaquine with primaquine
44 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
45 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
46 Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component Completed NCT00680732 Phase 4 Chloroquine (CQ);Sulphadoxyne-pyrimethamine (SP)
47 Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine Completed NCT01878357 Phase 4 dihydroartemisinin-piperaquine;primaquine
48 Improved Clinical and Microscopy Diagnosis at Primary Health Care in Tanzania Completed NCT00687895 Phase 4
49 Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area Completed NCT00935688 Phase 4
50 Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso Completed NCT01017770 Phase 4 Artesunate-amodiaquine;Artemether-lumefantrine

Search NIH Clinical Center for Malaria

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: malaria

Genetic Tests for Malaria

Genetic tests related to Malaria:

# Genetic test Affiliating Genes
1 Susceptibility to Malaria 29 ACKR1 CD36 CISH CR1 FCGR2A FCGR2B G6PD GYPA GYPB GYPC HBB ICAM1 NOS2 SLC4A1 TIRAP TNF

Anatomical Context for Malaria

MalaCards organs/tissues related to Malaria:

41
Testes, T Cells, Brain, Liver, Endothelial, Skin, Lung

Publications for Malaria

Articles related to Malaria:

(show top 50) (show all 4052)
# Title Authors Year
1
Immunization of malaria pre-exposed volunteers with PfSPZ Vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodies. ( 29438525 )
2018
2
RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype. ( 29439870 )
2018
3
<i>Anopheles</i> Salivary Biomarker as a Proxy for Estimating <i>Plasmodium falciparum</i> Malaria Exposure on the Thailand-Myanmar Border. ( 29869601 )
2018
4
Noninvasive measures of brain edema predict outcome in pediatric cerebral malaria. ( 29576904 )
2018
5
Treatment for Uncomplicated Plasmodium falciparum Malaria in French Soldiers Deployed in Sub-Saharan Africa: Gaps Between Policy and Field Practice. ( 29425320 )
2018
6
Therapeutic and Transmission-Blocking a8"Efficacy of Dihydroartemisinin/Piperaquine and Chloroquine against Plasmodium vivax Malaria, Cambodia. ( 29798745 )
2018
7
Efficacy of two artemisinin-based combinations for the treatment of malaria in pregnancy in India: a randomized controlled trial. ( 29973212 )
2018
8
Sensitivity of vegetation to climate variability and its implications for malaria risk in Baringo, Kenya. ( 29975780 )
2018
9
Epidemiological characteristics of malaria from control to elimination in Hubei Province, China, 2005-2016. ( 29448927 )
2018
10
Case Report: A Case of Severe Cerebral Malaria Managed with Therapeutic Hypothermia and Other Modalities for Brain Edema. ( 29405103 )
2018
11
Polymorphisms in TLRs influence circulating cytokines production in Plasmodium vivax malaria: TLR polymorphisms influence cytokine productions in malaria-vivax. ( 29656958 )
2018
12
Prevalence of and risk factors for malaria, filariasis, and intestinal parasites as single infections or co-infections in different settlements of Gabon, Central Africa. ( 29378644 )
2018
13
Acute disseminated encephalomyelitis, a rare post-malaria neurological complication: Case report and review of the literature. ( 29574241 )
2018
14
Multiplex serology for impact evaluation of bed net distribution on burden of lymphatic filariasis and four species of human malaria in northern Mozambique. ( 29444078 )
2018
15
Identifying Recrudescent Plasmodium falciparum in Treated Malaria Patients by Real-time PCR and High Resolution Melt Analysis of Genetic Diversity. ( 29973679 )
2018
16
Correction: Quantifying the contribution of <i>Plasmodium falciparum</i> malaria to febrile illness amongst African children. ( 29767625 )
2018
17
Prevalence of Neglected Tropical Diseases (Leishmaniasis and Lymphatic Filariasis) and Malaria Among a Migrant Labour Settlement in Kerala, India. ( 29860672 )
2018
18
Quantification of human complement factor H binding to asexual malaria blood stages by an enzyme-linked immunosorbent assay. ( 29449098 )
2018
19
Severe Plasmodium falciparum Malaria Treated With Investigational Artesunate in the United States. ( 29898630 )
2018
20
A Novel Single-Nucleotide Polymorphism Loop Mediated Isothermal Amplification Assay for Detection of Artemisinin-Resistant <i>Plasmodium falciparum</i> Malaria. ( 29707598 )
2018
21
<i>Plasmodium falciparum</i> Histidine-Rich Protein 2 Gene Variation in a Malaria-Endemic Area of Papua New Guinea. ( 29968556 )
2018
22
Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. ( 29447211 )
2018
23
Successful management of necrotizing pancreatitis in mixed malaria and review of literature. ( 29930900 )
2018
24
Stochastic lattice-based modelling of malaria dynamics. ( 29976221 )
2018
25
The complement system contributes to functional antibody-mediated responses induced by immunization with <i>Plasmodium falciparum</i> malaria sporozoites. ( 29735521 )
2018
26
Surveillance of Antimalarial Resistance Molecular Markers in Imported<i>Plasmodium falciparum</i>Malaria Cases in Anhui, China, 2012-2016. ( 29436339 )
2018
27
Trends of Plasmodium falciparum prevalence in two communities of Muheza district North-eastern Tanzania: correlation between parasite prevalence, malaria interventions and rainfall in the context of re-emergence of malaria after two decades of progressively declining transmission. ( 29976204 )
2018
28
Biological concepts in recurrent Plasmodium vivax malaria. ( 29564998 )
2018
29
Protein-Specific Features Associated with Variability in Human Antibody Responses to<i>Plasmodium falciparum</i>Malaria Antigens. ( 29141757 )
2018
30
Antibody responses to I+-Gal in African children vary with age and site and are associated with malaria protection. ( 29968771 )
2018
31
Regulation of Sexual Commitment and Gametocytogenesis in Malaria Parasites. ( 29975590 )
2018
32
Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. ( 29534720 )
2018
33
The Effect of ABO Blood Groups, Hemoglobinopathy, and Heme Oxygenase-1 Polymorphisms on Malaria Susceptibility and Severity. ( 29742871 )
2018
34
Cerebral Malaria in a Patient with HIV, Hepatitis B, and Hepatitis C. ( 29974024 )
2018
35
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. ( 29390987 )
2018
36
Chitinase-3-like 1 is a biomarker of acute kidney injury and mortality in paediatric severe malaria. ( 29448936 )
2018
37
Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk. ( 29599243 )
2018
38
Blackwater fever in a non-immune patient with Plasmodium falciparum malaria after intravenous artesunate. ( 29394389 )
2018
39
Efficacy of Artemether-Lumefantrine for Uncomplicated<i>Plasmodium falciparum</i>Malaria in Cruzeiro do Sul, Brazil, 2016. ( 29141762 )
2018
40
Promising approach to reducing Malaria transmission by ivermectin: Sporontocidal effect against Plasmodium vivax in the South American vectors Anopheles aquasalis and Anopheles darlingi. ( 29444080 )
2018
41
DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria. ( 29909070 )
2018
42
Acute respiratory distress syndrome and Plasmodium ovale malaria. ( 29886120 )
2018
43
Late onset acute pancreatitis in <i>P. falciparum</i> malaria - An adverse reaction to intravenous artesunate? ( 29942768 )
2018
44
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( 29889239 )
2018
45
Risk Factors for Mortality in Children Admitted for Suspected Malaria to a Pediatric Emergency Ward in a Low-Resource Setting: A Case-Control Study. ( 29979331 )
2018
46
Etiology of Placental Plasmodium falciparum Malaria in African Women. ( 29579263 )
2018
47
Spatio-temporal distribution of PfMDR1 polymorphism among uncomplicated Plasmodium falciparum malaria cases along international border of north east India. ( 29842979 )
2018
48
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger. ( 29370844 )
2018
49
Epidemiology, drug resistance, and pathophysiology of <i>Plasmodium vivax</i> malaria. ( 29916441 )
2018
50
Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. ( 29361939 )
2018